To the Editor:

The novel coronavirus SARS-CoV-2 (COVID-19) was recognized in December 2019 as a cause of severe pneumonia and has now led to a global pandemic.[@bib1] Respiratory illnesses caused by COVID-19 cover a range of severity. The identification of risk and protective factors for disease severity from COVID-19 is critical to direct development of new treatments and infection prevention strategies. Early large case series have identified a number of risk factors for severe disease, including older age, hypertension, diabetes, cardiovascular disease, tobacco exposure, and chronic obstructive pulmonary disease.[@bib2] The US Centers for Disease Control and Prevention lists asthma as a risk factor for severe COVID-19 illness, which is logical given that many respiratory viruses have been well established to cause more serious illnesses in those with chronic airway diseases such as asthma. However, asthma and respiratory allergy have not been identified as significant risk factors for severe COVID-19 illness in case series from China.[@bib2] These preliminary reports led us to question whether we could identify features of allergy and/or asthma that could be associated with potential for reduced severity of COVID-19 illness.

SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as its cellular receptor, as do SARS-CoV and the coronavirus NL63.[@bib1] Higher ACE2 expression increases *in vitro* susceptibility to SARS-CoV,[@bib3] and studies examining factors that affect *ACE2* gene expression have revealed that its upregulation is associated with smoking, diabetes, and hypertension, all of which are associated with increased severity of COVID-19 illness.[@bib4]

We hypothesized that 1 potential explanation for the unexpected observation that asthma and other allergic diseases may not be a risk factor for severe COVID-19 disease is a reduced *ACE2* gene expression in airway cells and thus decreased susceptibility to infection. To test this hypothesis, we examined whether asthma and respiratory allergy are associated with reduced *ACE2* expression in airway cells from 3 different cohorts of children and adults. In all 3 studies, total RNA was extracted from nasal or lower airway epithelial brush samples, with RNA sequencing performed independently for each study as previously described and provided in detail in the Supplementary Information (available in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0010}).[@bib5] Differential expression of *ACE2* was assessed by using a weighted linear mixed effects model (limma) appropriate for RNA sequencing data and an empiric Bayes method.

Children at high risk for asthma based on parental histories and living in urban neighborhoods were enrolled prenatally and followed prospectively in the Urban Environment and Childhood Asthma (URECA) cohort; 318 of them had nasal epithelial brushes obtained at 11 years of age. Prevalence of asthma was assessed at 10 years of age, and atopic status was defined by allergic sensitization trajectories (no or minimal, low, medium, and high) as previously described.[@bib6] Additional type 2 biomarkers, including fractional exhaled nitric oxide, peripheral blood eosinophil level, and total IgE level, were evaluated by using standard methods. In URECA, allergic sensitization was inversely related to *ACE2* expression in the nasal epithelium regardless of asthma status ([Fig 1](#fig1){ref-type="fig"} , *A*). In children with asthma, moderate allergic sensitization (fold change \[FC\] = 0.70; *P* = 4.2E--3) and high allergic sensitization (FC = 0.54; *P* = 6.4E--5) were associated with progressively greater reductions in *ACE2* expression compared with in children with asthma but no/minimal allergic sensitization ([Fig 1](#fig1){ref-type="fig"}, *B*). *ACE2* expression was also significantly inversely associated with type 2 biomarkers (see [Table E1](#tblE1){ref-type="table"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0015}), including the number of positive allergen-specific IgE test results (β coefficient --0.089; *P* = 3.1E--5), total IgE level (β coefficient --0.31; *P* = 5.1E--6), fractional exhaled nitric oxide (β coefficient --0.45; *P* = 3.4E--3), and nasal epithelial expression of *IL13* (β coefficient --0.123; *P* = 8.6E--5). *ACE2* expression was not significantly correlated with peripheral blood eosinophil level (β coefficient --0.13; *P* = .07). Although male sex has been associated with increased severity of COVID-19 illness,[@bib2] no sex-based differences in *ACE2* expression were found in URECA. Of note, 10 participants reported nasal corticosteroid use at the time of nasal sampling, and it was not associated with alterations in *ACE2* expression.Fig 1*ACE2* expression is decreased in the nasal epithelium of children with allergic sensitization (Sens) and allergic asthma. **A,***ACE2* expression levels in nasal brush samples from 11-year-old children in the URECA cohort according to asthma diagnosis by the age of 10 years, dichotomized as no (--) or yes (+), and IgE sensitization trajectory at the age of 10 years, dichotomized as not/minimally (no/Min) IgE-sensitized (--) or IgE-sensitized (+), showing lower levels of *ACE2* in children with atopy and atopic asthma. **B,***ACE2* expression in URECA children with asthma, subdivided according to the degree of IgE sensitization and demonstrating progressively lower levels of *ACE2* according to the degree of IgE sensitization among children with asthma. Those children with both asthma and the highest IgE sensitization had the lowest levels of *ACE2* expression. Expression levels are log2-transformed. Shown are median values (*horizontal*), interquartile ranges (*boxes*), and 1.5× interquartile range (*whiskers*). The printed FCs are for the non--log2-transformed expression values to aid in interpretation of the effect sizes.

We also evaluated 24 adult participants with allergic rhinitis to cat who had no asthma symptoms in the prior year, were enrolled in a study in which they underwent nasal cat allergen challenge (NAC), and had been exposed to cat allergen through an environmental exposure chamber (EEC), as previously described.[@bib5] Pre--allergen challenge and post--allergen challenge nasal brush samples were obtained. Allergen exposure by both NAC and EEC led to significant reductions in *ACE2* expression ([Fig 2](#fig2){ref-type="fig"} , *A*) (with NAC, FC = 0.81 and *P* = 2.4E--3; with exposure through an EEC, FC = 0.79 and *P* = 1.6E--3).Fig 2*ACE2* expression is decreased in nasal and bronchial epithelium of individuals with allergy after allergen challenge. **A,***ACE2* expression was significantly decreased in nasal brush samples from adults in the cohort with allergic rhinitis and cat allergen sensitization both 8 hours after a cat allergen NAC and 8 hours after the second day of a cat allergen EEC (n = 24) (<https://www.itntrialshare.org/CATEEC_primary.url>). **B,***ACE2* expression was significantly decreased in bronchial epithelial brush samples from adults with allergic asthma 48 hours after a segmental bronchial allergen challenge (n = 23). Expression levels are log2-transformed. Shown are median values (*horizontal*), interquartile ranges (*boxes*), and 1.5× interquartile range (*whiskers*). The printed FCs are for the non--log2-transformed expression values to aid in interpretation of the effect sizes.

An additional cohort of 23 adult participants with mild asthma that was not treated with asthma controller therapy underwent segmental allergen bronchoprovocation to dust mite, ragweed, or cat, as previously described.[@bib7] Pre--allergen challenge and post--allergen challenge bronchial brushings were obtained and demonstrated significantly reduced *ACE2* expression in lower airway epithelium in the post--allergen challenge samples ([Fig 2](#fig2){ref-type="fig"}, *B*) (FC 0.64; *P* = .01).

From *in vitro* models obtained from the Gene Expression Omnibus, we assessed the effects of IL-13, a type 2 cytokine strongly related to allergic asthma, on *ACE2* expression in differentiated airway epithelial cells. IL-13 significantly reduced *ACE2* expression (see [Fig E1](#figE1){ref-type="fig"} in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0020}) in both nasal (FC = 0.44; *P* = 5.8E--4) and bronchial (FC = 0.80; *P* = 5.1E--3) epithelium.

Viral respiratory infections are the most common trigger of severe asthma exacerbations in children and adults. Unexpectedly, large epidemiologic studies of the COVID-19 pandemic in China did not identify asthma as a risk factor of severe COVID-19--related illnesses.[@bib2] Here, we report that respiratory allergy and controlled allergen exposures are each associated with significant reductions in *ACE2* expression. *ACE2* expression was lowest in those with both high levels of allergic sensitization and asthma. Importantly, nonatopic asthma was not associated with reduced *ACE2* expression. Given that ACE2 serves as the receptor for SARS-CoV-2, our findings suggest a potential mechanism of reduced COVID-19 severity in patients with respiratory allergies. However, it is likely that additional factors beyond *ACE2* expression modulate the response to COVID-19 in individuals with allergy, and elucidation of these factors may also provide important insights into COVID-19 disease pathogenesis.

The strengths of our study include carefully phenotyped cohorts of children and adults. Further, the allergen challenge studies included both upper and lower airway samples, with each demonstrating a consistent impact on *ACE2* expression. The limitations include lack of clinical information to directly link *ACE2* expression to SARS-CoV-2 infection and illness severity in our study populations. In addition, we do not have data on the ACE2 protein levels to confirm the gene expression data, although previous work suggests a direct association between *ACE2* mRNA levels and ACE2 protein levels in the lung.[@bib8]

It is important to note that early data in the United States suggest a higher rate of asthma in patients hospitalized for severe COVID-19 illness, but the data do not specify whether the asthma was allergic, which is an important differentiation that relates to our findings. Nor do the data mention the potential presence of other comorbidities, such as obesity, that have been identified as risk factors for COVID-19 illness.[@bib9] Future studies focused on respiratory allergy, asthma, and perhaps other allergic disorders are needed to provide greater understanding of the impact of underlying allergy on COVID-19 susceptibility and disease severity. The modulation of *ACE2* expression by type 2 inflammatory processes suggests the need to comprehensively evaluate the role of type 2 immune regulation in COVID-19 pathogenesis. Further elucidation of these relationships could identify novel therapeutic strategies to more effectively control this pandemic.

Methods {#appsec1}
=======

In all 3 studies, total RNA was extracted from epithelial brush samples preserved in RLT buffer (Qiagen, Germantown, Md). Samples were thawed, vortexed, and quick-spun, after which the supernatant was transferred to fresh tubes. The samples were then spun through a Qiashredder column (Qiagen) and extracted by using RNeasy mini kits (Qiagen) with 25-μL elution volumes following the manufacturer's protocol. In the cat allergy upper airway challenge study, sequencing libraries were constructed from total RNA by using TruSeq RNA Sample Preparation Kits v2 (Illumina). In the URECA and adult asthma studies, sequencing libraries were constructed from total RNA by using SMART-Seq v4 Ultra Low Input RNA Kit (Takara). For each study, libraries were clustered onto a flow cell by using a cBOT amplification system with a HiSeq SR v4 Cluster Kit (Illumina). Single-read sequencing was carried out on a HiSeq2500 sequencer (Illumina), using a HiSeq SBS v4 Kit to generate 58-bp reads, with a target of approximately 10 million reads per sample. Samples for each study were processed and sequenced independently.

Reads were processed by using workflows managed on the Galaxy platform. Reads were trimmed by 1 base at the 3\' end and then trimmed from both ends until base calls had a minimum quality score of at least 30 (Galaxy FASTQ Trimmer tool \[version 1.0.0\]). FastqMcf (version 1.1.2) was used to remove any remaining adapter sequence. To align the trimmed reads, we used the STAR aligner with the GRCh38 reference genome and gene annotations from ensembl, release 91. Gene counts were generated by using HTSeq-count (version 0.4.1). For quality control, the samples kept were those that had counts greater than 1 million, more than 80% of reads aligned, and a median coefficient of variation (CV) coverage less than 1. Genes were filtered to include those that had a trimmed mean of M-value (TMM) normalization count of at least 1 in at least 10% of libraries and were classified as protein coding by using BioMart.[@bib10] Counts were transformed to log2 counts per million along with observation-level weights by using voomWithQualityWeights from the limma R package[@bib11] to create a weighted gene expression matrix suitable for downstream analyses.

Differential expression of *ACE2* was assessed independently in each data set by using a weighted linear mixed effects model (limma) appropriate for RNA sequencing data and an empiric Bayes method.[@bib11], [@bib12] Mixed effects linear regression models were used; they included relevant clinical or technical variables (for URECA, cytologically determined cell percentages in the brush and the clinical site were used; for the upper airway challenge study, processing batch was used; and for the adult asthma study, no fixed effects were included) and a random effect of participant in both of the airway challenge studies. *P* values less than .05 were considered statistically significant.

We searched the National Center for Biotechnology Information Gene Expression Omnibus for the terms *IL13* and *epithelial* subset to the organism *Homo sapiens*.[@bib13] From this we identified 2 studies investigating the effects of IL-13 stimulation on human airway epithelial cells grown at an air-liquid interface that had repeated measures in the IL-13 stimulation and unstimulated groups. In the GSE110799 study, human nasal epithelial cells isolated from nasal turbinates were cultured in an air-liquid interface until the full differentiation was complete, after which the differentiated cells at ALI-D47 were incubated with 100 ng/mL of IL-13 for 3 days. In GSE37693, RNA was isolated from primary culture airway epithelial cells grown at an air-liquid interface treated with or without IL-13 for 21 days.[@bib14] Differential expression analysis was performed by using GEO2R, which performs voom and limma[@bib11], [@bib12] in the National Center for Biotechnology Information\'s Gene Expression Omnibus browser. Fig E1IL-13 stimulation decreases *ACE2* expression in nasal and bronchial epithelium. IL-13 stimulation of airway epithelial cells grown in an air-liquid interface decreased *ACE2* expression in nasal epithelium (FC = 0.44; *P* = 5.8E--4; n = 2 per condition) **(A)** and bronchial epithelium (FC = 0.80; *P* = 5.1E--3; n = 4 per condition) **(B)**. Shown are mean expression levels (*red*) and individual points representing biologic replicates.Table E1Association of T2 biomarkers and nasal brush *ACE2* expression in the URECA cohortBiomarkerAssociation with *ACE2***e**xpression (β coefficient)*P* valuePositive allergen-specific IgE--0.0893.1E--5Total IgE level--0.315.1E--6Fractional exhaled nitric oxide--0.453.4E--3Blood eosinophils--0.13.07Nasal epithelial *IL****-****13 e*xpression--0.1238.6E--5
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